<DOC>
	<DOCNO>NCT01922856</DOCNO>
	<brief_summary>The purpose study determine efficacy vaccine enterotoxigenic E. coli ( ETEC ) -caused diarrhea .</brief_summary>
	<brief_title>Challenge Study ETEC Vaccine</brief_title>
	<detailed_description>The purpose study establish preliminary efficacy dscCfaE administer LTR192G intradermal ( ID ) immunization prevention disease cause challenge CFA/I express ETEC strain ( H10407 ) .</detailed_description>
	<mesh_term>Enteritis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female age 18 50 year ( inclusive ) . General good health , without clinically significant medical history , physical examination finding clinical laboratory abnormality per clinical judgment PI . Negative pregnancy test . Pregnancy time result receive additional investigational product . Females childbearing potential must agree use efficacious hormonal barrier method birth control study . Abstinence acceptable . Female subject unable bear child must document ( eg , tubal ligation hysterectomy ) must negative pregnancy test . Willingness participate study aspect protocol explain write informed consent obtain . Completion train session demonstrate comprehension protocol procedure , knowledge ETECassociated illness , pass write examination ( 70 % pass score ) . Availability study duration , include plan followup visit . General Presence significant medical psychiatric condition opinion investigator precludes participation study . Some medical condition adequately treat stable would preclude entry study . These condition might include stable asthma control inhaler mild hypertension stably control single agent . Significant abnormality screen hematology , serum chemistry determine PI PI consultation research monitor sponsor . Presence serum HIV antibody , HBsAg , HCV antibody . Evidence IgA deficiency ( serum IgA &lt; 7 mg/dL limit detection assay ) . Evidence current excessive alcohol consumption drug dependence ( target drug screen may use evaluate clinician 's discretion ) . Evidence impair immune function . Recent vaccination receipt investigational product ( within 30 day vaccination ) . Any criterion , investigator 's opinion , would compromise ability subject participate study , safety study , result study Research Related Exclusions Applicable Vaccination Challenge Participation History microbiologically confirm ETEC cholera infection last 3 year . Occupation involve handle ETEC Vibrio cholerae currently , past 3 year . Symptoms consistent Travelers ' Diarrhea concurrent travel country ETEC infection endemic ( develop world ) within 3 year prior dose , OR plan travel endemic country length study . Vaccination ingestion ETEC , cholera , E coli heat labile toxin within 3 year prior dose . Research Related Exclusions Not Applicable ChallengeOnly Participants Exclusionary skin history/findings would confound assessment prevent appropriate local monitoring AEs , possibly increase risk AE . History chronic skin disease ( clinician judgment ) . History atopy active eczema . Acute skin infection/eruptions upper arm include fungal infection , severe acne , active contact dermatitis . History significant allergic reaction vaccine allergy may increase risk AEs ( Wellcontrolled seasonal allergy responsive antihistamine medication intranasal steroid exclusionary per clinician determination ) . Studyspecific Exclusion Criteria Abnormal stool pattern ( few 3 per week 3 per day ) . Regular use laxative , antacid , agent low stomach acidity . Use medication know affect immune function ( eg , systemic corticosteroid others ) within 30 day precede first vaccination plan use active study period . Known allergy two follow antibiotic : ciprofloxacin , trimethoprimsulfamethoxazole , penicillin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>